# A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06279364/  
OnCo record `nct06279364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Capecitabine, Eribulin and Carboplatin in triple-negative breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT06279364 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 524 participants planned, started 2024-02-28 and due to reach its primary completion in 2026-07. Interventions recorded: SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin and Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06279364
- Phase: 3
- Setting: A Randomized, Open-Label, Multicenter Phase 3 Study of SKB264 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 524

## Sources

- ClinicalTrials.gov NCT06279364: https://clinicaltrials.gov/study/NCT06279364

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Eribulin](https://onco.cc/drugs/eribulin/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct06279364.json